HealthTell, winner of the 2012 “Innovator of the Year, Start-Up Company,” was praised by the Arizona Technology Council for its development of a new method of monitoring patients’ health statuses. HealthTell’s technology takes a novel approach to the problem of detecting cancer and infectious diseases before they spread or become harder to treat. Unlike other methods which focus on measuring the pathogen and require complicated and expensive monitoring devices, HealthTell’s Click here to read more…

 

Crenezumab, an experimental Alzheimer’s drug manufactured by Genentech, will be the first drug to be tested for efficacy in Alzheimer’s prevention. The drug was chosen from a pool of 25 competitors, primarily because Crenezumab–unlike many similar drugs–does not cause vasogenic edema (brain swelling). The landmark trials are slated to begin in early 2013 and will be important in determining whether early intervention can prevent or slow the onset of Alzheimer’s Click here to read more…

 

Scientists from UCLA’s School of Medicine genetically engineered tomatoes to product 6F–a peptide that mimics the chief protein in HDL (“good cholesterol”). The tomatoes were consumed by mice that did not have the ability to purge LDL (“bad cholesterol”) from their blood. The mice that ate the genetically engineered tomatoes “had less inflammation and reduced atherosclerosis (plaque build-up in the arteries)” and had higher levels of HDL (details of effects Click here to read more…

 

Researchers from Cornell Medical College report that mass spectrometry (which is a tool commonly used to identify lipids and proteins by weighing individual molecules) can for the first time ever give scientists insight into how antibiotics work inside living cells to kill microbes. This new application of mass spectrometry can enhance our ability to develop more effective and less drug-resistant antibiotics. The need for new antibiotics is a particularly pressing Click here to read more…